Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial

The Lancet

Volumn 394, Issue 10198, 2019, Pages 576-586

  Reich, Kristian ^a   Gooderham, Melinda ^b,c   Thaçi, Diamant ^d   Crowley, Jeffrey J ^e   Ryan, Caitriona ^f   Krueger, James G ^g   Tsai, Tsen Fang ^h   Flack, Mary ⁱ   Gu, Y ^j   Williams, David A ^j   Thompson, Elizabeth H Z ^j   Paul, C ^k  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b QUEEN S UNIVERSITY   (Canada)

^c SKiN Centre for Dermatology and Probity Medical Research Inc   (Canada)

^d UNIVERSITY OF LÜBECK   (Germany)

^e Bakersfield Dermatology and Skin Cancer Medical Group   (United States)

^f UNIVERSITY COLLEGE DUBLIN   (Ireland)

^g ROCKEFELLER UNIVERSITY   (United States)

^h NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

ⁱ BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^j ABBVIE INC   (United States)

^k UNIVERSITÉ DE TOULOUSE   (France)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; RISANKIZUMAB; MONOCLONAL ANTIBODY;

ACUTE HEART INFARCTION; ADULT; ADVERSE OUTCOME; ARTICLE; BREAST CARCINOMA; CHOLELITHIASIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; FEMALE; GALLBLADDER CANCER; HUMAN; LATENT TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PSORIASIS VULGARIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG ADMINISTRATION; MULTICENTER STUDY; PSORIASIS; SUBCUTANEOUS DRUG ADMINISTRATION;

ADALIMUMAB; ADULT; ANTIBODIES, MONOCLONAL; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PSORIASIS;

EID: 85070540421     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(19)30952-3     Document Type: Article

References (29)

1. Harden, JL, Krueger, JG, Bowcock, AM, The immunogenetics of psoriasis: a comprehensive review. J Autoimmun 64 (2015), 66–73.
2. WHO. 2016 Global report on psoriasis. http://www.who.int/iris/handle/10665/204417, 2016. (Accessed 12 September 2018)
3. Oppmann, B, Lesley, R, Blom, B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 13 (2000), 715–725.
4. Gooderham, MJ, Papp, KA, Lynde, CW, Shifting the focus-the primary role of IL-23 in psoriasis and other inflammatory disorders. J Eur Acad Dermatol Venereol 32 (2018), 1111–1119.
5. Puig, L, PASI90 response: the new standard in therapeutic efficacy for psoriasis. J Eur Acad Dermatol Venereol 29 (2015), 645–648.
6. Papp, KA, Langley, RG, Lebwohl, M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371 (2008), 1675–1684.
7. Blauvelt, A, Papp, KA, Griffiths, CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol 76 (2017), 405–417.
8. Reich, K, Armstrong, AW, Foley, P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo-and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol 76 (2017), 418–431.
9. Reich, K, Papp, KA, Blauvelt, A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet 390 (2017), 276–288.
10. Ibler, E, Gordon, KB, IL-23 inhibitors for moderate-to-severe psoriasis. Semin Cutan Med Surg 37 (2018), 158–162.
11. Kleinschek, MA, Muller, U, Brodie, SJ, et al. IL-23 enhances the inflammatory cell response in Cryptococcus neoformans infection and induces a cytokine pattern distinct from IL-12. J Immunol 176 (2006), 1098–1106.
12. Singh, S, Kroe-Barrett, RR, Canada, KA, et al. Selective targeting of the IL23 pathway: generation and characterization of a novel high-affinity humanized anti-IL23A antibody. MAbs 7 (2015), 778–791.
13. Gordon, KB, Strober, B, Lebwohl, M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet 392 (2018), 650–661.
14. Kane, D, FitzGerald, O, Tumor necrosis factor-alpha in psoriasis and psoriatic arthritis: a clinical, genetic, and histopathologic perspective. Curr Rheumatol Rep 6 (2004), 292–298.
15. US Food and Drug Administration, Center for Drug Evaluation and Research. Humira BL 125057/110 approval letter. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2008/125057s0110ltr.pdf, 2008. (Accessed 3 October 2018)
16. Iskandar, IYK, Ashcroft, DM, Warren, RB, et al. Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Br J Dermatol 176 (2017), 1297–1307.
17. Krueger, JG, Ferris, LK, Menter, A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol, 136, 2015, 116 24.e7.
18. Papp, KA, Blauvelt, A, Bukhalo, M, et al. Risankizumab versus ustekinumab for moderate-to-severe plaque psoriasis. N Engl J Med 376 (2017), 1551–1560.
19. Augustin, M, Reich, K, Glaeske, G, Schaefer, I, Radtke, M, Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 90 (2010), 147–151.
20. Bernstein, CN, Wajda, A, Blanchard, JF, The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 129 (2005), 827–836.
21. Wolf, N, Quaranta, M, Prescott, NJ, et al. Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease. J Med Genet 45 (2008), 114–116.
22. Hohenberger, M, Cardwell, LA, Oussedik, E, Feldman, SR, Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat 29 (2018), 13–18.
23. Menter, A, Tyring, SK, Gordon, K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 58 (2008), 106–115.
24. Saurat, JH, Stingl, G, Dubertret, L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 158 (2008), 558–566.
25. Carlin, CS, Feldman, SR, Krueger, JG, Menter, A, Krueger, GG, A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. J Am Acad Dermatol 50 (2004), 859–866.
26. Manalo, IF, Gilbert, KE, Wu, JJ, Time to raise the bar to Psoriasis Area Severity Index 90 and 100. J Drugs Dermatol 14 (2015), 1086–1088.
27. Strober, B, Papp, KA, Lebwohl, M, et al. Clinical meaningfulness of complete skin clearance in psoriasis. J Am Acad Dermatol 75 (2016), 77–82 e7.
28. Sanford, M, McKeage, K, Secukinumab: first global approval. Drugs 75 (2015), 329–338.
29. Langley, RG, Elewski, BE, Lebwohl, M, et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371 (2014), 326–338.